Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
The 2024 Raleigh Christmas Parade: What to know
Recommended
Top holiday events in the Triangle: Tree lightings, parades, and festive markets await
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Syndax Pharma
(NQ:
SNDX
)
15.83
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Syndax Pharma
< Previous
1
2
3
4
Next >
Do Penny Stocks Ever Make Money? Here Are 7 Success Stories
April 10, 2022
Penny stocks can make money. Success stories include Advanced Micro Devices, a former penny stock that earned a $3.2 billion net income in 2021. Here are six others.
Via
InvestorPlace
Syndax Pharmaceuticals's Return On Capital Employed Overview
March 07, 2022
According to Benzinga Pro, during Q4, Syndax Pharmaceuticals (NASDAQ:SNDX) earned $96.20 million, a 566.1% increase from the preceding quarter. Syndax Pharmaceuticals also posted...
Via
Benzinga
Recap: Syndax Pharmaceuticals Q4 Earnings
March 01, 2022
Syndax Pharmaceuticals (NASDAQ:SNDX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2022
February 15, 2022
Upgrades For Blue Bird Corp (NASDAQ:BLBD), Roth Capital upgraded the previous rating of Neutral to Buy. Blue Bird earned $0.07 in the first quarter, compared to $0.00 in the year-...
Via
Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
February 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
December 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 16, 2021
Gainers Calliditas Therapeutics (NASDAQ:CALT) stock rose 41.09% to $26.3 during Thursday's pre-market session. The market value of their outstanding shares is at $688....
Via
Benzinga
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
December 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug...
Via
Benzinga
Syndax Pharma Posts Additional Data On Clinical Activity, Responses From Early-Stage Leukemia Trial
December 14, 2021
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with...
Via
Benzinga
Earnings Preview For Syndax Pharmaceuticals
November 12, 2021
Syndax Pharmaceuticals (NASDAQ:SNDX) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement....
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 04, 2021
Gainers Evaxion Biotech (NASDAQ:EVAX) stock moved upwards by 157.5% to $16.74 during Thursday's regular session. Evaxion Biotech's stock is trading at a volume of...
Via
Benzinga
Earnings Scheduled For November 15, 2021
November 15, 2021
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter. • Tyson Foods (NYSE:TSN) is estimated to...
Via
Benzinga
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
November 14, 2021
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 05, 2021
Gainers Ocugen (NASDAQ:OCGN) shares moved upwards by 11.11% to $7.5 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.4...
Via
Benzinga
81 Biggest Movers From Yesterday
November 05, 2021
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8...
Via
Benzinga
55 Stocks Moving In Thursday's Mid-Day Session
November 04, 2021
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the...
Via
Benzinga
Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate
September 27, 2021
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
September 27, 2021
Gainers Syndax Pharmaceuticals (NASDAQ:SNDX) shares moved upwards by 8.94% to $20.48 during Monday's pre-market session. The company's market cap stands at $995.9...
Via
Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...
Via
Benzinga
Syndax Pharmaceuticals's Return On Capital Employed Insights
September 14, 2021
According to data from Benzinga Pro, during Q2, Syndax Pharmaceuticals's (NASDAQ:SNDX) reported sales totaled $379.00 thousand. Despite a 17.78% increase in earnings, the...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
September 09, 2021
Gainers IVERIC bio (NASDAQ:ISEE) shares ...
Via
Benzinga
Earnings Scheduled For August 9, 2021
August 09, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...
Via
Benzinga
44 Stocks Moving In Monday's Mid-Day Session
June 28, 2021
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software...
Via
Benzinga
Syndax Pharmaceuticals: Return On Capital Employed Insights
June 18, 2021
In Q1, Syndax Pharmaceuticals (NASDAQ:SNDX) posted sales of $379.00 thousand. Earnings were up 36.77%, but Syndax Pharmaceuticals still reported an overall loss of $27.16 million...
Via
Benzinga
Return On Capital Employed Overview: Syndax Pharmaceuticals
June 03, 2021
In Q1, Syndax Pharmaceuticals (NASDAQ:SNDX) posted sales of $379.00 thousand. Earnings were up 36.77%, but Syndax Pharmaceuticals still reported an overall loss of $27.16 million...
Via
Benzinga
Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia Trial
May 12, 2021
Syndax Pharmaceuticals Inc (NASDAQ: SNDX), in its Q1 earnings, also announced new data from the ongoing Phase 1 dose-escalation portion of the Phase 1/2...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to...
Via
Benzinga
Recap: Syndax Pharmaceuticals Q1 Earnings
May 11, 2021
Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 3.57% year...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.